RBT-101
/ Radiant Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 04, 2025
Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting
(Businesswire)
- "RBT-101, Radiant’s lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model....RBT-101 demonstrated long-lived anti-tumor immunological memory; no detectable tumor growth was observed in mice that were re-challenged with MC38 tumor cells after previous successful treatment."
Preclinical • Colorectal Cancer
September 11, 2024
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody Platform
(Businesswire)
- "Radiant Biotherapeutics...announced it has closed a $35 million Series A financing. The round is co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures of Canada....The funds will enable Radiant to further develop the company’s lead clinical candidate, 4-1BB, and move it towards clinical trials."
Financing • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1